These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 36127374)

  • 1. Small soluble α-synuclein aggregates are the toxic species in Parkinson's disease.
    Emin D; Zhang YP; Lobanova E; Miller A; Li X; Xia Z; Dakin H; Sideris DI; Lam JYL; Ranasinghe RT; Kouli A; Zhao Y; De S; Knowles TPJ; Vendruscolo M; Ruggeri FS; Aigbirhio FI; Williams-Gray CH; Klenerman D
    Nat Commun; 2022 Sep; 13(1):5512. PubMed ID: 36127374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging protein aggregates in the serum and cerebrospinal fluid in Parkinson's disease.
    Lobanova E; Whiten D; Ruggeri FS; Taylor CG; Kouli A; Xia Z; Emin D; Zhang YP; Lam JYL; Williams-Gray CH; Klenerman D
    Brain; 2022 Apr; 145(2):632-643. PubMed ID: 34410317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha Synuclein only Forms Fibrils In Vitro when Larger than its Critical Size of 70 Monomers.
    Sanchez SE; Whiten DR; Meisl G; Ruggeri FS; Hidari E; Klenerman D
    Chembiochem; 2021 Oct; 22(19):2867-2871. PubMed ID: 34383993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cofilin 1 promotes the aggregation and cell-to-cell transmission of α-synuclein in Parkinson's disease.
    Yan M; Meng L; Dai L; Zhang X; Chen G; Zheng Y; Zha Y; Zeng Y; Zhang Z
    Biochem Biophys Res Commun; 2020 Sep; 529(4):1053-1060. PubMed ID: 32819564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-Synuclein Nitration and Its Implications in Parkinson's Disease.
    He Y; Yu Z; Chen S
    ACS Chem Neurosci; 2019 Feb; 10(2):777-782. PubMed ID: 30183251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative super-resolution imaging of pathological aggregates reveals distinct toxicity profiles in different synucleinopathies.
    Morten MJ; Sirvio L; Rupawala H; Mee Hayes E; Franco A; Radulescu C; Ying L; Barnes SJ; Muga A; Ye Y
    Proc Natl Acad Sci U S A; 2022 Oct; 119(41):e2205591119. PubMed ID: 36206368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective detection, quantification, and subcellular location of alpha-synuclein aggregates with a protein aggregate filtration assay.
    Kramer ML; Behrens C; Schulz-Schaeffer WJ
    Biotechniques; 2008 Mar; 44(3):403-11. PubMed ID: 18361794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DJ-1, a Parkinson's disease related protein, aggregates under denaturing conditions and co-aggregates with α-synuclein through hydrophobic interaction.
    Zhu M; H Patel S; Han S
    Biochim Biophys Acta Gen Subj; 2017 Jul; 1861(7):1759-1769. PubMed ID: 28330770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease.
    van Rooijen BD; Claessens MM; Subramaniam V
    Curr Protein Pept Sci; 2010 Aug; 11(5):334-42. PubMed ID: 20423294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease.
    Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-Synuclein Proximity Ligation Assay (AS-PLA) in Brain Sections to Probe for Alpha-Synuclein Oligomers.
    Roberts RF; Bengoa-Vergniory N; Alegre-Abarrategui J
    Methods Mol Biol; 2019; 1948():69-76. PubMed ID: 30771171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients.
    Recasens A; Carballo-Carbajal I; Parent A; Bové J; Gelpi E; Tolosa E; Vila M
    Acta Neuropathol Commun; 2018 Feb; 6(1):8. PubMed ID: 29422109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and Aggregation Properties of Alpha-Synuclein Linked to Phospholipase A2 Action.
    Broersen K; Ruiperez V; Davletov B
    Protein Pept Lett; 2018; 25(4):368-378. PubMed ID: 29577851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease.
    Nordström E; Eriksson F; Sigvardson J; Johannesson M; Kasrayan A; Jones-Kostalla M; Appelkvist P; Söderberg L; Nygren P; Blom M; Rachalski A; Nordenankar K; Zachrisson O; Amandius E; Osswald G; Moge M; Ingelsson M; Bergström J; Lannfelt L; Möller C; Giorgetti M; Fälting J
    Neurobiol Dis; 2021 Dec; 161():105543. PubMed ID: 34737044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging Protein Aggregates in Parkinson's Disease Serum Using Aptamer-Assisted Single-Molecule Pull-Down.
    Zhang YP; Lobanova E; Emin D; Lobanov SV; Kouli A; Williams-Gray CH; Klenerman D
    Anal Chem; 2023 Oct; 95(41):15254-15263. PubMed ID: 37782556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
    Sharma N; Rao SP; Kalivendi SV
    Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copper and iron ions accelerate the prion-like propagation of α-synuclein: A vicious cycle in Parkinson's disease.
    Li Y; Yang C; Wang S; Yang D; Zhang Y; Xu L; Ma L; Zheng J; Petersen RB; Zheng L; Chen H; Huang K
    Int J Biol Macromol; 2020 Nov; 163():562-573. PubMed ID: 32629061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMT-3 targets different α-synuclein aggregates mitigating their toxic and inflammogenic effects.
    González-Lizárraga F; Ploper D; Ávila CL; Socías SB; Dos-Santos-Pereira M; Machín B; Del-Bel E; Michel PP; Pietrasanta LI; Raisman-Vozari R; Chehín R
    Sci Rep; 2020 Nov; 10(1):20258. PubMed ID: 33219264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.